在这个试验中，入选标准为年龄大于45岁经历保乳手术的浸润性导管癌的患者。
In this trial, women aged at least 45 years with invasive ductal breast carcinoma undergoing breast-conserving surgery were enrolled.
浸润性导管癌发病率最高，占44.9%，其次为单纯癌，占34.3%。
Infiltrating duct cancer was a high incidence (44.9%) and the secondary was simple cancer (34.3%).
浸润性导管癌发病率最高，占44.9%，其次为单纯癌，占34.3%。
Infiltrating duct cancer was a high incidence (44.9%) and the secondary was simple cancer (34.3%).
应用推荐